

# Scientific Panel on Food Additives and Nutrient Sources added to Food (ANS)

## Minutes of the 59<sup>th</sup> Plenary meeting

Held on 27-29 October 2015, Parma (Italy)

(Agreed on 17 November 2015)

### Participants

#### a) Panel Members

Fernando Aguilar,<sup>1</sup> Riccardo Crebelli, Alessandro Di Domenico, Birgit Dusemund, Maria José Frutos,<sup>2</sup> Pierre Galtier, David Gott, Ursula Gundert-Remy, Claude Lambré, Jean-Charles Leblanc,<sup>2</sup> Peter Moldeus, Alicja Mortensen, Pasquale Mosesso, Agneta Oskarsson, Dominique Parent-Massin, Ivan Stankovic, Ine Waalkens-Berendsen, Rudolf Antonius Woutersen, Matthew Wright<sup>3</sup>, Maged Younes

#### b) Hearing experts<sup>4</sup>

Daniel Marzin<sup>5</sup>

#### c) European Commission and/or Member States representatives:

- Jiri Sochor (DG SANTE E7)

#### d) EFSA:

- Food Ingredients and Packaging (FIP) Unit: Dario Battacchi, Anna Christodoulidou, Paolo Colombo, Juho Lemmetyinen, Federica Lodi, Ana Maria Rincon, Claudia Roncancio Peña, Camilla Smeraldi, Alexandra Tard, Stavroula Tasiopoulou
- DATA Unit: Davide Arcella

### 1. Welcome and apologies for absence

The Chair welcomed all participants.

Apologies were received from Oliver Lindtner.

<sup>1</sup> Participated via teleconference on 27 October PM (agenda item 6.2)

<sup>2</sup> Participated on 28 and 29 October

<sup>3</sup> Participated on 27 and 28 October

<sup>4</sup> As defined in Article 11 of the Decision of the Executive Director on Declarations of Interest: <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

<sup>5</sup> Participated via teleconference on 28 October AM (agenda item 6.4)

## 2. Adoption of agenda

The agenda was adopted without any changes.

## 3. Declarations of Interest of Scientific Committee/Scientific Panel/ Members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes<sup>2</sup> and the Decision of the Executive Director on Declarations of Interest,<sup>3</sup> EFSA screened the Annual Declarations of Interest and the Specific Declarations of Interest filled in by the Scientific Panel Members invited for the present meeting. For further details on the outcome of the screening of the ADoI or the SDoI, please refer to Annex. Oral Declaration of Interest was asked at the beginning of the meeting and no additional interest was declared.

## 4. Agreement of the minutes of the 58<sup>th</sup> Plenary meeting held on 8-10 September 2015, Parma (Italy)

The minutes of the 58<sup>th</sup> Plenary meeting held on 8-10 September were agreed.<sup>4</sup>

## 5. Report on the written procedures since 58th Plenary meeting

No scientific outputs were adopted by written procedure since the last plenary meeting.

## 6. Scientific outputs submitted for discussion and possible adoption

### 6.1 Request for EFSA to provide a scientific opinion on the safety of the proposed extension of use of Thaumatin (E 957) as a food additive ([EFSA-Q-2015-00117](#))

The rapporteur introduced the draft opinion on the safety assessment of the proposed extension of use of thaumatin (E 957) to the members of the ANS Panel and presented the main points for discussion. The ANS Panel discussed the different parts of the risk assessment and adopted the opinion subject to incorporation of changes as suggested during the meeting.

The full opinion is available on the [Authority's webpage](#).

### 6.2 Re-evaluation of E 120 Cochineal, carminic acid, carmines ([EFSA-Q-2011-00360](#))

The rapporteur introduced the draft opinion on the safety assessment of Cochineal, carminic acid, carmines (E 120) to the members of the ANS Panel and presented the main points for discussion.

The ANS Panel discussed the different parts of the risk assessment and adopted the opinion subject to incorporation of changes as suggested during the meeting.

The full opinion is available on the [Authority's webpage](#).

### 6.3 Re-evaluation of E 304(i) Ascorbyl palmitate; L-ascorbyl palmitate; 2,3-didehydro-L-threo- hexono-1,4-lactone-6-palmitate; 6-

<sup>2</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencpolicy.pdf>

<sup>3</sup> <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

<sup>4</sup> <http://www.efsa.europa.eu/en/events/event/150609>

**palmitoyl-3-keto-L-gulofuranolactone ([EFSA-Q-2011-00473](#)) , E 304(ii) Ascorbyl stearate; L-ascorbyl stearate; 2,3-didehydro-L-threo-hexono- 1,4-lactone-6-stearate; 6-stearoyl-3-keto-L-gulofuranolactone ([EFSA-Q-2011-00474](#))**

The rapporteur introduced the draft opinion on the safety assessment of ascorbyl palmitate (E 304(i)) and ascorbyl stearate (E 304(ii)) to the members of the ANS Panel and presented the main points for discussion.

The ANS Panel discussed the different parts of the risk assessment and adopted the opinion subject to incorporation of changes as suggested during the meeting.

The full opinion is available on the [Authority's webpage](#).

**6.4 Re-evaluation of E 242 Dimethyl dicarbonate ([EFSA-Q-2011-00459](#))**

The rapporteur introduced the draft opinion on the safety assessment of dimethyl dicarbonate (E 242) to the members of the ANS Panel and presented the main points for discussion.

Initial discussion took place on the technical sections and the hazard characterization. The need for further clarifications before finalization was noted. Final discussion and adoption of the opinion are deferred to an upcoming plenary meeting.

**6.5 Re-evaluation of E 172 Iron oxides and hydroxides (i), (ii), (iii) ([EFSA-Q-2011-00347](#))**

The rapporteur introduced the draft opinion on the safety assessment of iron oxide and hydroxides E 172 (i)(ii)(iii) to the members of the ANS Panel and presented the main points for discussion.

Initial discussion took place on the technical sections and the hazard characterization. The need for further clarifications before finalization was noted. Final discussion and adoption of the opinion are deferred to an upcoming plenary meeting.

**6.6 Re-evaluation of E 162 Beetroot red ([EFSA-Q-2011-00350](#))**

This topic was not discussed because of lack of time.

**6.7 Re-evaluation of E 210 Benzoic acid ([EFSA-Q-2011-00001](#)), E 211 sodium benzoate ([EFSA-Q-2011-00002](#)), E 212 potassium benzoate ([EFSA-Q-2011-00003](#)), E 213 calcium benzoate ([EFSA-Q-2011-00004](#))**

This topic was not discussed because of lack of time.

## **7. New Mandates**

The update on mandates is deferred to the next Plenary meeting.

## **8. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission**

### **8.1 Scientific Committee and Scientific Panel including their Working Groups**

#### **8.1.1. ANS SWG Re-evaluation of Nitrates – Nitrites**

#### **8.1.2 ANS WG Isoflavones**

#### **8.1.3 ANS SWG Re-evaluation of Food Colours**

#### **8.1.4 ANS SWG Re-evaluation of Gums and Food Additives from Natural Sources**

#### **8.1.5 ANS SWG Re-evaluation of Food Additives other than Gums & Colours**

#### **8.1.6 ANS SWG on Applications**

The update on progress made by the Working Groups is deferred to the next Plenary meeting.

### **8.2 EFSA including its Working Groups /Task Forces**

- Food labels database – Global New Products Database (GNPD): a scientific officer from DATA Unit made a presentation on the use of the database
- The Panel Chair reported on the content of the draft guidance on uncertainty in scientific assessment and on the next steps for Panel experts in term of training, trial period and timelines.

### **8.3 European Commission**

No specific topics were reported by the European Commission representative.

## **9. Other scientific topics for information and/or discussion**

### **9.1 Extension of use of E 950 acesulfame K in dietary foods for young children for special medical purposes ([EFSA-Q-2015-00134](#))**

The rapporteur requested steering from the Panel on the approach to be taken in assessing the safety of this specific extension of use of acesulfame K.

### **9.2 Re-evaluation of E 171 Titanium dioxide ([EFSA-Q-2011-00348](#))**

The Chair of the Working Group “Colours” reported about the status of the scientific opinion and a discussion on technical aspects was held. Further discussion is deferred to an upcoming working group meeting.

## **10. Any Other Business**

None